GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Mankind Pharma Ltd

Mankind Pharma Board Approves Amalgamation of Wholly-Owned Subsidiaries

M&A ● No Immediate Change LOW RISK
📅 Filed on BSE: 26 Oct 2026, 03:21 PM IST  ·  BSE ID: 07efccfc-9d73-4e3f-9cd9-89c7283233fa
View Original BSE Filing (PDF)
💡
In Simple Terms
Mankind Pharma is simplifying its structure by merging two wholly-owned subsidiaries into itself and another subsidiary.
🤖 AI Summary
  • Mankind Pharma Board approved scheme for amalgamation of Prolijune Lifesciences and Pavi Buildwell into Mankind Pharma.
  • Both Prolijune Lifesciences and Pavi Buildwell are wholly-owned subsidiaries of Mankind Pharma Limited.
  • The appointed date for the amalgamation scheme is set as April 01, 2027.
  • Board also noted scheme for amalgamation of Upakarma Ayurveda Private Limited with Mankind Consumer Products Private Limited.
  • All amalgamation schemes are subject to necessary statutory and regulatory approvals.
🏢 How This Affects the Company
📈
Business Impact
The amalgamation of wholly-owned subsidiaries into the parent company can lead to greater operational efficiencies and streamlined business processes for Mankind Pharma Limited.
💰
Financial Impact
Consolidating wholly-owned subsidiaries is a step towards simplifying the corporate structure, which may result in reduced administrative and compliance costs over time.
⚙️
Operational Impact
Integrating Prolijune Lifesciences and Pavi Buildwell with Mankind Pharma can optimize resource allocation and enhance synergy across the consolidated entity.
⚠️
Risk Impact
The proposed schemes are subject to various statutory and regulatory approvals, including from the NCLT, which introduces a procedural risk until all consents are secured.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders as the schemes are subject to regulatory approvals.
👤
Who Is Affected
All shareholders of Mankind Pharma Limited are indirectly affected by the corporate restructuring, which aims to consolidate wholly-owned subsidiaries for operational efficiency.
🔍
Management Signal
Management is signaling a focus on corporate simplification and synergy creation by consolidating wholly-owned subsidiaries through amalgamation schemes.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
NCLT approval for amalgamation Scheme 1 for Prolijune and Pavi Buildwell.
Receipt of all necessary statutory and regulatory approvals for Scheme 1.
Progress on approvals for Scheme 2 regarding Upakarma Ayurveda and Mankind Consumer Products.
LOW RISK The schemes involve wholly-owned subsidiaries and are primarily procedural, subject to standard regulatory approvals.
💡 Investor Takeaway
Mankind Pharma's Board approved schemes to amalgamate wholly-owned subsidiaries Prolijune Lifesciences and Pavi Buildwell into the parent company, with an appointed date of April 01, 2027. This structural simplification aims for enhanced operational efficiency, pending regulatory approvals.
⚖️ Strengths & Concerns

✅ Positives

  • Streamlined corporate structure by amalgamating wholly-owned subsidiaries, potentially reducing complexity and administrative overhead.
  • The direct amalgamation of wholly-owned subsidiaries is exempt from No-Objection Letters from Stock Exchanges under Regulation 37(6).

⚠️ Concerns

  • The amalgamation schemes require various statutory and regulatory approvals, including from the National Company Law Tribunal, delaying final implementation.
  • The appointed date for Scheme 1 is April 01, 2027, indicating a future effective date for the operational changes.
📅 Company Track Record
Mankind Pharma has been actively involved in M&A recently, including acquiring a 70% stake in ACTx for EUR 48Mn in October 2026 and fully acquiring Upakarma Ayurveda for ₹75 Lakhs cash in June 2026. In March 2026, it acquired the Rivotril CNS brand from Roche.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What did Mankind Pharma's Board approve regarding amalgamation?
The Board approved the Scheme of Arrangement for amalgamation of Prolijune Lifesciences Private Limited and Pavi Buildwell Private Limited, both wholly-owned subsidiaries, into Mankind Pharma Limited.
What is the appointed date for the amalgamation of Prolijune Lifesciences and Pavi Buildwell?
The appointed date for the amalgamation scheme of Prolijune Lifesciences and Pavi Buildwell with Mankind Pharma Limited is April 01, 2027.
Which other amalgamation scheme was noted by Mankind Pharma's Board?
The Board noted the Scheme of Arrangement for amalgamation of Upakarma Ayurveda Private Limited with Mankind Consumer Products Private Limited, a wholly-owned subsidiary of Mankind Pharma.
Are these amalgamation schemes immediately effective?
No, these schemes are subject to necessary statutory and regulatory approvals, including from the Hon'ble National Company Law Tribunal.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.